A meta‐analysis of primary HCC patients revealed that a preoperative serum GGT concentration ≥ 38 U/L independently predicts the risk of recurrence and all‐cause mortality in patients with HBV‐associated HCC who are undergoing surgical resection (especially patients with tumors > 5 cm and who are treated with liver transplantation) and is a cost‐effective prognostic tumor biomarker for HCC resection, especially when the AFP concentration is ≤ 200 ng/mL in hepatocellular carcinoma patients [121]. Here, GGTLC3 is linked to neoplasm.